Michael A. Nauck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael A. Nauck has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Juris J. Meier
Diabeteszentrum Bad Lauterberg
5 shared publications- Jens Juul Holst
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
3 shared publications Andrea El-Ouaghlidi
2 shared publicationsIrfan Vardarli
Diabetes Center Bad Lauterberg, Kircherg 21, Bad Lauterberim Harz, Niedersachsen, D-37431, Germany
2 shared publicationsJ. J. Meier
Ruhr-University Bochum
2 shared publicationsA Mügge
Departments of Medicine I and II, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany
1 shared publication
Latest Publications
- 1 October 2017
- Published by Georg Thieme Verlag KG in Diabetologie und Stoffwechsel
- Vol. 12 (S 02) , S141-S156
Therapie des Typ-2-Diabetes
Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft (DDG) zusammen mit der Deutschen Gesellschaft für Innere Medizin (DGIM) lehnen sich eng an die Inhalte der Nationalen VersorgungsLeitlinie (NVL) „Therapie des Typ-2-Diabetes“ an. Die in diesen Praxisempfehlungen abgebildeten Inhalte sind zum großen Teil die konsentierten Abschnitte der ganzen Arbeitsgruppe, die für die Erarbeitung der Nationalen VersorgungsLeitlinie verantwortlich war. Umfangreiche Details einschließlich der wissenschaftlichen Belege finden Sie in der Langfassung der NVL (http://www.versorgungsleitlinien.de).
- 1 October 2017
- Published by Georg Thieme Verlag KG in Diabetologie und Stoffwechsel
- Vol. 12 (S 02) , S141-S156
Therapie des Typ-2-Diabetes
Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft (DDG) zusammen mit der Deutschen Gesellschaft für Innere Medizin (DGIM) lehnen sich eng an die Inhalte der Nationalen VersorgungsLeitlinie (NVL) „Therapie des Typ-2-Diabetes“ an. Die in diesen Praxisempfehlungen abgebildeten Inhalte sind zum großen Teil die konsentierten Abschnitte der ganzen Arbeitsgruppe, die für die Erarbeitung der Nationalen VersorgungsLeitlinie verantwortlich war. Umfangreiche Details einschließlich der wissenschaftlichen Belege finden Sie in der Langfassung der NVL (http://www.versorgungsleitlinien.de).
- 25 March 2013
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 138 (S 01) , S4-S6
SGLT-2-Inhibitor Dapagliflozin: Neuer Therapieansatz für den Typ-2-Diabetes, neue Erfolge, aber auch neue Fragen!
- 25 March 2013
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 138 (S 01) , S4-S6
SGLT-2-Inhibitor Dapagliflozin: Neuer Therapieansatz für den Typ-2-Diabetes, neue Erfolge, aber auch neue Fragen!
- 25 September 2010
- Published by Springer Nature in Diabetologia
- Vol. 54 (1) , 10-18
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting postprandial insulin secretion. Since GLP-1 may play a role in the pathophysiology and treatment of type 2 diabetes, assessment of meal-related GLP-1 secretory responses in type 2 diabetic patients vs healthy individuals is of great interest. A common view states that GLP-1 secretion in patients with type 2 diabetes is deficient and that this applies to a lesser degree in individuals with impaired glucose tolerance. Such a deficiency is the rationale for replacing endogenous incretins with GLP-1 receptor agonists or re-normalising active GLP-1 concentrations with dipeptidyl peptidase-4 inhibitors. This review summarises the literature on this topic, including a meta-analysis of published studies on GLP-1 secretion in individuals with and without diabetes after oral glucose and mixed meals. Our analysis does not support the contention of a generalised defect in nutrient-related GLP-1 secretory responses in type 2 diabetes patients. Rather, factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake.
- 25 September 2010
- Published by Springer Nature in Diabetologia
- Vol. 54 (1) , 10-18
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting postprandial insulin secretion. Since GLP-1 may play a role in the pathophysiology and treatment of type 2 diabetes, assessment of meal-related GLP-1 secretory responses in type 2 diabetic patients vs healthy individuals is of great interest. A common view states that GLP-1 secretion in patients with type 2 diabetes is deficient and that this applies to a lesser degree in individuals with impaired glucose tolerance. Such a deficiency is the rationale for replacing endogenous incretins with GLP-1 receptor agonists or re-normalising active GLP-1 concentrations with dipeptidyl peptidase-4 inhibitors. This review summarises the literature on this topic, including a meta-analysis of published studies on GLP-1 secretion in individuals with and without diabetes after oral glucose and mixed meals. Our analysis does not support the contention of a generalised defect in nutrient-related GLP-1 secretory responses in type 2 diabetes patients. Rather, factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake.
- Open Access
- 1 February 2010
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 1 (1-2) , 24-36
Comparative evaluation of incretin‐based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure†
Aims/Introduction: To compare clinical consequences of using inretin‐based medications versus conventional antidiabetic agents as add‐on to metformin in case of monotherapy failure in patients with type 2 diabetes.Materials and Methods: The medical literature including recent abstracts from international diabetes conferences was searched for reports from clinical trials with incretin mimetics (GLP‐1 receptor agonists), inhibitors of dipeptidyl peptidase‐4 (DPP‐4, incretin enhancers) and conventional antidiabtic drugs coadministered with metformin after monotherapy failure. A scoring system is suggested to compare the clinical utility of using incretin‐based versus conventional antidiabetic agents in this situation.Results: Incretin mimetics and DPP‐4 inhibitors on top of metformin treatment help achieve glycaemic control comparable to other efficient antidiabetic drugs, both if separate or head‐to‐head trials were considered. Incretin‐based antidiabetic drugs did not cause hypoglycaemia (different from sulfonylureas, meglitinides and insulin) and weight gain (different from sulfonylureas, meglitinides, thiazolidinediones, and insulin). DPP‐4 inhibitors were weight neutral, incretin mimetics lead to weight loss. The clinical profile of incretin‐based medications received the highest scores, followed by α‐glucosidase inhibitors, with far lower scores assigned to insulin, glitazones, and sulfonyureas (in this order).Conclusions: Based on the results from clinical trials, incretin‐based medications have been shown to be efficacious antidiabetic drugs with a favourable adverse event and tolerability profile. This leads to high scores using a novel system paying attention to multiple facets contributing to the selection of antidiabetic drugs for general recommendation and individual treatment choices.
- 1 February 2010
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 1 (1-2) , 24-36
Open AccessComparative evaluation of incretin‐based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure†
Aims/Introduction: To compare clinical consequences of using inretin‐based medications versus conventional antidiabetic agents as add‐on to metformin in case of monotherapy failure in patients with type 2 diabetes.Materials and Methods: The medical literature including recent abstracts from international diabetes conferences was searched for reports from clinical trials with incretin mimetics (GLP‐1 receptor agonists), inhibitors of dipeptidyl peptidase‐4 (DPP‐4, incretin enhancers) and conventional antidiabtic drugs coadministered with metformin after monotherapy failure. A scoring system is suggested to compare the clinical utility of using incretin‐based versus conventional antidiabetic agents in this situation.Results: Incretin mimetics and DPP‐4 inhibitors on top of metformin treatment help achieve glycaemic control comparable to other efficient antidiabetic drugs, both if separate or head‐to‐head trials were considered. Incretin‐based antidiabetic drugs did not cause hypoglycaemia (different from sulfonylureas, meglitinides and insulin) and weight gain (different from sulfonylureas, meglitinides, thiazolidinediones, and insulin). DPP‐4 inhibitors were weight neutral, incretin mimetics lead to weight loss. The clinical profile of incretin‐based medications received the highest scores, followed by α‐glucosidase inhibitors, with far lower scores assigned to insulin, glitazones, and sulfonyureas (in this order).Conclusions: Based on the results from clinical trials, incretin‐based medications have been shown to be efficacious antidiabetic drugs with a favourable adverse event and tolerability profile. This leads to high scores using a novel system paying attention to multiple facets contributing to the selection of antidiabetic drugs for general recommendation and individual treatment choices.
- 11 September 2009
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 106 (37) , 587-AR1
Self-Monitoring of Blood Glucose in Diabetes Mellitus
Metabolic self-monitoring, such as urine and blood glucose self-measurement is a controversial topic. At the center of the discussions are the type, timing, and frequency of measures as well as issues of cost reimbursement. On the one hand, reliable...
- 11 September 2009
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 106 (37) , 587-AR1
Self-Monitoring of Blood Glucose in Diabetes Mellitus
Metabolic self-monitoring, such as urine and blood glucose self-measurement is a controversial topic. At the center of the discussions are the type, timing, and frequency of measures as well as issues of cost reimbursement. On the one hand, reliable...
- 1 August 2009
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 23 (4) , 513-523
Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
- 1 August 2009
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 23 (4) , 513-523
Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
- 1 July 2009
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 20, S303-S308
Unraveling the Science of Incretin Biology
- 1 July 2009
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 20, S303-S308
Unraveling the Science of Incretin Biology
- 1 June 2009
- Published by Elsevier in The American Journal of Medicine
- Vol. 122 (6) , S3-S10
Unraveling the Science of Incretin Biology
- 1 June 2009
- Published by Elsevier in The American Journal of Medicine
- Vol. 122 (6) , S3-S10
Unraveling the Science of Incretin Biology
- 1 November 2008
- Published by SAGE Publications in British Journal of Diabetes
- Vol. 8 (2_suppl) , S26-S33
Liraglutide, a once-daily human GLP-1 analogue
Glucagon-like peptide-1 (GLP-1) is an incretin hormone physiologically playing a role in glucose homeostasis, together with the partner incretin, glucose dependent insulinotropic peptide (GIP). Active concentrations of this hormone are not maintained for long because of its very rapid degradation and elimination. The effects of the hormone are of potential therapeutic value in type 2 diabetes; therefore, analogues of GLP-1 have been developed that are characterised by a prolonged circulating half-life relative to the naturally occurring hormone. One such long-acting analogue is liraglutide. The effects of liraglutide are maintained over 24 h, allowing once-daily dosing. Liraglutide provides all of the beneficial actions of endogenous GLP-1: glucose-dependent stimulation of insulin secretion, glucagon suppression, deceleration of gastric emptying, appetite suppression/weight loss and, in animal models, inhibition of β-cell apoptosis and promotion of β-cell regeneration. Because liraglutide stimulates insulin secretion and suppresses glucagon secretion only when blood glucose levels are elevated, the risk of treatment-associated hypoglycaemia is low. In clinical studies, liraglutide substantially lowered fasting and postprandial glucose concentrations, with an overall reduction in haemoglobin A1c of up to 1-2%. In some studies, liraglutide has decreased several biomarkers of cardiovascular risk and lowered triglyceride levels significantly. Side effects most commonly are gastrointestinal symptoms; they are usually mild to moderate and resolve over time. Long-term clinical trials are needed to assess whether the effects of liraglutide on the β cell translate into a durable improvement in β-cell function and mass in patients with type 2 diabetes and, if so, whether this will slow or halt disease progression and help prevent complications.Br J Diabetes Vasc Dis, 2008; 8 (Suppl 2): S26—S33
- 1 November 2008
- Published by SAGE Publications in British Journal of Diabetes
- Vol. 8 (2_suppl) , S26-S33
Liraglutide, a once-daily human GLP-1 analogue
Glucagon-like peptide-1 (GLP-1) is an incretin hormone physiologically playing a role in glucose homeostasis, together with the partner incretin, glucose dependent insulinotropic peptide (GIP). Active concentrations of this hormone are not maintained for long because of its very rapid degradation and elimination. The effects of the hormone are of potential therapeutic value in type 2 diabetes; therefore, analogues of GLP-1 have been developed that are characterised by a prolonged circulating half-life relative to the naturally occurring hormone. One such long-acting analogue is liraglutide. The effects of liraglutide are maintained over 24 h, allowing once-daily dosing. Liraglutide provides all of the beneficial actions of endogenous GLP-1: glucose-dependent stimulation of insulin secretion, glucagon suppression, deceleration of gastric emptying, appetite suppression/weight loss and, in animal models, inhibition of β-cell apoptosis and promotion of β-cell regeneration. Because liraglutide stimulates insulin secretion and suppresses glucagon secretion only when blood glucose levels are elevated, the risk of treatment-associated hypoglycaemia is low. In clinical studies, liraglutide substantially lowered fasting and postprandial glucose concentrations, with an overall reduction in haemoglobin A1c of up to 1-2%. In some studies, liraglutide has decreased several biomarkers of cardiovascular risk and lowered triglyceride levels significantly. Side effects most commonly are gastrointestinal symptoms; they are usually mild to moderate and resolve over time. Long-term clinical trials are needed to assess whether the effects of liraglutide on the β cell translate into a durable improvement in β-cell function and mass in patients with type 2 diabetes and, if so, whether this will slow or halt disease progression and help prevent complications.Br J Diabetes Vasc Dis, 2008; 8 (Suppl 2): S26—S33
- Open Access
- 1 November 2008
- Published by SAGE Publications in British Journal of Diabetes
- Vol. 8 (2_suppl) , S1-S2
The modulating effects of GLP-1 in type 2 diabetes
- 1 November 2008
- Published by SAGE Publications in British Journal of Diabetes
- Vol. 8 (2_suppl) , S1-S2
Open AccessThe modulating effects of GLP-1 in type 2 diabetes